Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
SEATTLE, WA / ACCESSWIRE / April 11, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
COVID-19
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population...
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in...
Aptevo Therapeutics Provides Pipeline Update
Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now...
AgriCann Solutions Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - AgriCann Solutions Corp. ("AgriCann") (with its subsidiaries, collectively referred to as...
Gemina Labs Announces Addition to its IP Portfolio
VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it...
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing...
Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market
AhealthZ to aid Nanox’s pursuit of local authorizations and licenses for Nanox.ARC in South Korea SCL Science to integrate Nanox’s...
Mainz Biomed Reports Full Year 2023 Financial Results
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of...
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast...
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,...
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or...
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024PARIS, FRANCE AND CAMBRIDGE,...
electroCore Announces the Launch of Truvaga Plus® for General Wellness
ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Results of the Combined General Meeting on April 2, 2024
All resolutions presented by the Company have been adoptedPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 /...
Killer Heart Disease Epidemic Sweeping UK As It Faces ‘Worst Heart Care Crisis in Living Memory’, Cardiologist Warns
LONDON, UK / ACCESSWIRE / April 4, 2024 / The UK is ‘in the grip of the worst heart care...
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidateKey takeaways:Participants in...
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strainsFor influenza A strains, geometric mean titers numerically...